Catalyst Wire Dossier Catalyst Wire Dossier

tarextumab

tarextumab · OncoMed Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for tarextumab, covering 2019-05-01 to 2023-02-15. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer [Phase 1, Phase 2]

See pricing